Role of Biologics in the Development of Autoimmune Hepatitis: A Review

Overview

Journal J Clin Transl Hepatol

Specialty Gastroenterology

Date 2019 Jan 15

PMID 30637218

Citations 3

Authors

Leon D Averbukh

George Y Wu

Affiliations

Soon will be listed here.

Abstract

Autoimmune hepatitis (AIH) is a cause of chronic, immune-mediated liver injury which without treatment may progress to end-stage liver disease. The disease state, characterized by elevations in liver enzymes, autoantibodies, and interface hepatitis on histology, has been noted to be induced by a wide range of insults. Medications, most commonly minocycline and nitrofurantoin, have long been established as potential inducers of AIH. Recently, biologics, powerful immune-modulators, have also been reported to induce AIH. We conclude that there is an association between administration of biologics in the development of AIH, and whether the relationship is causal will require appropriate studies in the future.

Citing Articles

Statin-induced Liver Injury Patterns: A Clinical Review.

Averbukh L, Turshudzhyan A, Wu D, Wu G J Clin Transl Hepatol. 2022; 10(3):543-552.

PMID: 35836753 PMC: 9240239. DOI: 10.14218/JCTH.2021.00271.

Autoimmune hepatitis triggered by COVID-19.

Hong J, Chopra S, Kahn J, Kim B, Khemichian S Intern Med J. 2021; 51(7):1182-1183.

PMID: 34278694 PMC: 8447478. DOI: 10.1111/imj.15420.

Biologic and Checkpoint Inhibitor-Induced Liver Injury: A Systematic Literature Review.

Shah P, Sundaram V, Bjornsson E Hepatol Commun. 2020; 4(2):172-184.

PMID: 32025603 PMC: 6996412. DOI: 10.1002/hep4.1465.

References

Keane J, Gershon S, Wise R, Kasznica J, Schwieterman W, Siegel J . Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001; 345(15):1098-104. DOI: 10.1056/NEJMoa011110. View

Boberg K . Prevalence and epidemiology of autoimmune hepatitis. Clin Liver Dis. 2002; 6(3):635-47. DOI: 10.1016/s1089-3261(02)00021-1. View

Brekke O, Sandlie I . Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov. 2003; 2(1):52-62. DOI: 10.1038/nrd984. View

Vergani D, Mieli-Vergani G . Autoimmune hepatitis. Autoimmun Rev. 2003; 2(5):241-7. DOI: 10.1016/s1568-9972(03)00017-x. View

Diamantis I, Boumpas D . Autoimmune hepatitis: evolving concepts. Autoimmun Rev. 2004; 3(3):207-14. DOI: 10.1016/j.autrev.2003.09.003. View

Eriksson C, Engstrand S, Sundqvist K, Rantapaa-Dahlqvist S . Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis. 2004; 64(3):403-7. PMC: 1755409. DOI: 10.1136/ard.2004.024182. View

Germano V, Picchianti Diamanti A, Baccano G, Natale E, Onetti Muda A, Priori R . Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis. 2005; 64(10):1519-20. PMC: 1755231. DOI: 10.1136/ard.2004.032821. View

Krawitt E . Autoimmune hepatitis. N Engl J Med. 2006; 354(1):54-66. DOI: 10.1056/NEJMra050408. View

Zalevsky J, Secher T, Ezhevsky S, Janot L, Steed P, OBrien C . Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol. 2007; 179(3):1872-83. DOI: 10.4049/jimmunol.179.3.1872. View

10.

Marques M, Magro F, Cardoso H, Carneiro F, Portugal R, Lopes J . Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis. Inflamm Bowel Dis. 2007; 14(5):723-5. DOI: 10.1002/ibd.20293. View

11.

Ozorio G, McGarity B, Bak H, Jordan A, Lau H, Marshall C . Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. Med J Aust. 2007; 187(9):524-6. DOI: 10.5694/j.1326-5377.2007.tb01396.x. View

12.

Krawitt E . Clinical features and management of autoimmune hepatitis. World J Gastroenterol. 2008; 14(21):3301-5. PMC: 2716584. DOI: 10.3748/wjg.14.3301. View

13.

Harada K, Akai Y, Koyama S, Ikenaka Y, Saito Y . A case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis. Clin Rheumatol. 2008; 27(8):1063-6. DOI: 10.1007/s10067-008-0885-1. View

14.

Fairhurst D, Sheehan-Dare R . Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriaisis. Clin Exp Dermatol. 2009; 34(3):421-2. DOI: 10.1111/j.1365-2230.2008.03088.x. View

15.

Adar T, Mizrahi M, Pappo O, Scheiman-Elazary A, Shibolet O . Adalimumab-induced autoimmune hepatitis. J Clin Gastroenterol. 2009; 44(1):e20-2. DOI: 10.1097/MCG.0b013e3181a745e7. View

16.

Poulin Y, Therien G . Drug-induced hepatitis and lupus during infliximab treatment for psoriasis: case report and literature review. J Cutan Med Surg. 2010; 14(2):100-4. DOI: 10.2310/7750.2009.09007. View

17.

Manns M, Czaja A, Gorham J, Krawitt E, Mieli-Vergani G, Vergani D . Diagnosis and management of autoimmune hepatitis. Hepatology. 2010; 51(6):2193-213. DOI: 10.1002/hep.23584. View

18.

Goujon C, Dahel K, Berard F, Guillot I, Gunera-Saad N, Nicolas J . Autoimmune hepatitis in two psoriasis patients treated with inflixmab. J Am Acad Dermatol. 2010; 63(2):e43-4. DOI: 10.1016/j.jaad.2009.02.029. View

19.

Ngu J, Bechly K, Chapman B, Burt M, Barclay M, Gearry R . Population-based epidemiology study of autoimmune hepatitis: a disease of older women?. J Gastroenterol Hepatol. 2010; 25(10):1681-6. DOI: 10.1111/j.1440-1746.2010.06384.x. View

20.

Czaja A . Performance parameters of the conventional serological markers for autoimmune hepatitis. Dig Dis Sci. 2010; 56(2):545-54. DOI: 10.1007/s10620-010-1501-1. View